Chemo Brain in Cancer Patients: What Is It and How Can It Be Managed?

Harnessing PIPAC to Improve Outcomes in Peritoneal Carcinomatosis

The MALT1 inhibitor demonstrated a favorable safety profile and tolerability in findings from a phase 1 clinical trial presented at the EHA 2025 Congress.

Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.

Benjamin J. Golas, MD

AI-Based Urine Test Earns FDA Breakthrough Device Status in Bladder Cancer

Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.

Use of the novel artificial intelligence–based test may provide a painless, low-cost alternative in bladder cancer screening.

Practice-Changing Lung Cancer Data From the 2025 ASCO Annual Meeting

Use of the novel artificial intelligence–based test may provide a painless, low-cost alternative in bladder cancer screening.

Stephen Liu, MD, and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.

Stephen V. Liu, MD;Joshua K. Sabari, MD

June 23rd 2025

High Tumor Volume Confers CAR T-Cell Therapy Toxicity Risk in LBCL

Stephen Liu, MD; and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.

Data support incorporating volumetric PET biomarkers into toxicity risk prediction for patients receiving CAR T-cell therapy for LBCL.

SGR-1505 Earns Fast Track Designation for R/R Waldenström Macroglobulinemia

Data support incorporating volumetric PET biomarkers into toxicity risk prediction for patients receiving CAR T-cell therapy for LBCL.

Related Content

Roman Fabbricatore

Harnessing PIPAC to Improve Outcomes in Peritoneal Carcinomatosis

The MALT1 inhibitor demonstrated a favorable safety profile and tolerability in findings from a phase 1 clinical trial presented at the EHA 2025 Congress.

Benjamin J. Golas, MD

AI-Based Urine Test Earns FDA Breakthrough Device Status in Bladder Cancer

Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.

Practice-Changing Lung Cancer Data From the 2025 ASCO Annual Meeting

Use of the novel artificial intelligence–based test may provide a painless, low-cost alternative in bladder cancer screening.

Stephen V. Liu, MD;Joshua K. Sabari, MD

June 23rd 2025

High Tumor Volume Confers CAR T-Cell Therapy Toxicity Risk in LBCL

Stephen Liu, MD; and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.